The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations

MLA

Adam M. Bailis, et al. “The RAD52 S346X Variant Reduces Risk of Developing Breast Cancer in Carriers of Pathogenic Germline BRCA2 Mutations.” Molecular Oncology, vol. 14, no. 6, June 2020, pp. 1124–33. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....abaa055bd073038a058051bf0b7a6eb9&authtype=sso&custid=ns315887.

APA

Adam M. Bailis, Yuan Chun Ding, Jeremy M. Stark, Aaron Adamson, Carlos Mendez-Dorantes, & Susan L. Neuhausen. (2020). The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations. Molecular Oncology, 14(6), 1124–1133.

Chicago

Adam M. Bailis, Yuan Chun Ding, Jeremy M. Stark, Aaron Adamson, Carlos Mendez-Dorantes, and Susan L. Neuhausen. 2020. “The RAD52 S346X Variant Reduces Risk of Developing Breast Cancer in Carriers of Pathogenic Germline BRCA2 Mutations.” Molecular Oncology 14 (6): 1124–33. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....abaa055bd073038a058051bf0b7a6eb9&authtype=sso&custid=ns315887.